EXPO · Exponent Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $582.01M | $558.51M | $536.77M | $513.29M | $466.27M | $399.90M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $25.52M | $22.73M | $24.44M | $23.66M | $15.28M | $12.89M |
| Total Operating Expenses | $462.23M | $438.96M | $425.44M | $372.45M | $357.34M | $316.65M |
| D&A | $10.08M | $9.69M | $8.92M | $7.08M | $6.49M | $6.87M |
| Operating Income | $119.79M | $119.56M | $111.32M | $140.84M | $108.93M | $83.25M |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $41.29M | $38.37M | $35.56M | $29.90M | $24.64M | $14.38M |
| Net Income | $106.01M | $109.00M | $100.34M | $102.33M | $101.20M | $82.55M |
| EPS - Basic | $2.08 | $2.13 | $1.96 | $1.98 | $1.92 | $1.58 |
| EPS - Diluted | $2.07 | $2.11 | $1.94 | $1.96 | $1.90 | $1.55 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $221.93M | $258.90M | $187.15M | $161.46M | $297.69M | $197.53M |
| Accounts Receivable | $181.51M | $161.41M | $167.36M | $170.11M | $139.86M | $111.56M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $6.87M | $5.27M | $4.49M | $8.64M | $3.19M | $3.28M |
| Current Assets | $427.58M | $446.88M | $379.53M | $349.16M | $452.76M | $366.83M |
| Total Assets | $777.52M | $777.27M | $646.78M | $586.66M | $683.74M | $580.10M |
| Current Liabilities | $178.00M | $163.18M | $161.91M | $159.03M | $152.98M | $117.31M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $387.18M | $356.20M | $290.69M | $265.91M | $266.67M | $218.60M |
| Stockholders' Equity | $390.34M | $421.07M | $356.08M | $320.75M | $417.06M | $361.50M |
| Retained Earnings | $668.42M | $624.15M | $574.08M | $528.81M | $478.37M | $421.81M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $131.73M | $144.54M | $127.35M | $93.81M | $124.57M | $103.31M |
| Investing Cash Flow | ($9.39M) | ($6.94M) | ($16.36M) | ($12.04M) | $38.18M | $5.02M |
| Financing Cash Flow | ($160.43M) | ($65.11M) | ($86.01M) | ($215.98M) | ($62.75M) | ($88.36M) |
| CapEx | $9.39M | $6.94M | $16.36M | $12.04M | $6.83M | $4.99M |
| Free Cash Flow | $122.34M | $137.60M | $111.00M | $81.76M | $117.74M | $98.33M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 20.6% | 21.4% | 20.7% | 27.4% | 23.4% | 20.8% |
| EBITDA margin | 22.3% | 23.1% | 22.4% | 28.8% | 24.8% | 22.5% |
| Net margin | 18.2% | 19.5% | 18.7% | 19.9% | 21.7% | 20.6% |
| Free cash flow margin | 21.0% | 24.6% | 20.7% | 15.9% | 25.3% | 24.6% |
| FCF / Net income | 1.15 | 1.26 | 1.11 | 0.80 | 1.16 | 1.19 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 4.4% | 4.1% | 4.6% | 4.6% | 3.3% | 3.2% |
| Effective tax rate | 28.0% | 26.0% | 26.2% | 22.6% | 19.6% | 14.8% |
| Return on assets | 13.6% | 14.0% | 15.5% | 17.4% | 14.8% | 14.2% |
| Return on equity | 27.2% | 25.9% | 28.2% | 31.9% | 24.3% | 22.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.40 | 2.74 | 2.34 | 2.20 | 2.96 | 3.13 |
| Quick ratio | 2.40 | 2.74 | 2.34 | 2.20 | 2.96 | 3.13 |
| Cash ratio | 1.25 | 1.59 | 1.16 | 1.02 | 1.95 | 1.68 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.99 | 1.85 | 1.82 | 1.83 | 1.64 | 1.60 |
| Liabilities / Assets | 0.50 | 0.46 | 0.45 | 0.45 | 0.39 | 0.38 |
| Efficiency | ||||||
| Asset turnover | 0.75 | 0.72 | 0.83 | 0.87 | 0.68 | 0.69 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 114d | 105d | 114d | 121d | 109d | 102d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 33.9x | 42.1x | 45.4x | 50.6x | 61.4x | 58.1x |
| P / B | 9.2x | 10.9x | 12.8x | 16.2x | 14.9x | 13.3x |
| P / S | 6.2x | 8.2x | 8.5x | 10.1x | 13.4x | 12.0x |
| EV / EBITDA | 26.0x | 33.5x | 36.3x | 33.9x | 51.4x | 51.1x |
| Growth | ||||||
| Revenue growth (YoY) | 4.2% | 4.1% | 4.6% | 10.1% | 16.6% | -4.1% |
| Revenue CAGR (3y) | 4.3% | 6.2% | 10.3% | 7.2% | 7.1% | 4.8% |
| Revenue CAGR (5y) | 7.8% | 6.0% | 7.2% | 8.1% | 8.2% | 5.0% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 0.2% | 7.4% | -21.0% | 29.3% | 30.8% | -2.2% |
| Net income growth (YoY) | -2.7% | 8.6% | -1.9% | 1.1% | 22.6% | 0.1% |
| EPS growth (YoY) | -1.9% | 8.8% | -1.0% | 3.2% | 22.6% | 1.3% |
| EPS CAGR (3y) | 1.8% | 3.6% | 7.8% | 8.6% | 12.6% | 0.4% |
| EPS CAGR (5y) | 6.0% | 6.6% | 7.8% | 5.1% | 1.7% | -0.6% |
| FCF growth (YoY) | -11.1% | 24.0% | 35.8% | -30.6% | 19.7% | 15.6% |
| FCF CAGR (5y) | 4.5% | 10.1% | 8.2% | 8.0% | 17.5% | 12.3% |
| Book value growth (YoY) | -7.3% | 18.2% | 11.0% | -23.1% | 15.4% | 3.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-01-02.
Business segments
$582.01M totalEngineering And Other Scientific$493.89M · 84.9%
Environmental And Health$88.12M · 15.1%
Geographic
$582.01M totalUS$520.59M · 89.4%
Non Us$61.42M · 10.6%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
2.61
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Management Consulting Services
Comparing EXPONENT INC against the 5 most active filers in the same SIC group.
Dividends
$1.21/share trailing 12 months · +6.1% YoY
| Ex-date | Per share |
|---|---|
| Mar 6, 2026 | $0.3100 |
| Dec 5, 2025 | $0.3000 |
| Sep 5, 2025 | $0.3000 |
| Jun 6, 2025 | $0.3000 |
| Mar 7, 2025 | $0.3000 |
| Dec 6, 2024 | $0.2800 |
| Sep 6, 2024 | $0.2800 |
| Jun 7, 2024 | $0.2800 |
| Mar 7, 2024 | $0.2800 |
| Dec 7, 2023 | $0.2600 |
| Sep 7, 2023 | $0.2600 |
| Jun 8, 2023 | $0.2600 |
| Mar 9, 2023 | $0.2600 |
| Dec 8, 2022 | $0.2400 |
| Sep 8, 2022 | $0.2400 |
| Jun 9, 2022 | $0.2400 |
| Mar 10, 2022 | $0.2400 |
| Dec 2, 2021 | $0.2000 |
| Sep 9, 2021 | $0.2000 |
| Jun 10, 2021 | $0.2000 |
| Mar 11, 2021 | $0.2000 |
| Dec 3, 2020 | $0.1900 |
| Sep 10, 2020 | $0.1900 |
| Jun 11, 2020 | $0.1900 |